{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T04:24:11Z","timestamp":1741926251596,"version":"3.38.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To investigate for association between skin autofluorescence (SAF) advanced glycation end products (AGEs) and uveitis\/scleritis activity in systemic inflammatory disease-related active non-infectious uveitis\/scleritis patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This cross-sectional study was conducted at Siriraj Hospital during October 2019 to March 2020. AGEs were measured by SAF method in systemic immune-related disease patients with active uveitis\/scleritis, and those results were compared with those of healthy age-matched controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Thirty-one active non-infectious uveitis\/scleritis patients and 31 age-matched controls were enrolled. The mean age of patients was 40.0\u2009\u00b1\u200912.8 years, and most were female (55.0%). The most common associated systemic immune-related disease was Vogt\u2013Koyanagi\u2013Harada disease (<jats:italic>n<\/jats:italic>\u2009=\u200914). Mean SAF AGE level in the study group compared to the control group was 2.38\u2009\u00b1\u20090.66 arbitrary units (AU) versus 2.58\u2009\u00b1\u20090.56 AU, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.20). Multivariate analysis showed decreased SAF AGE level to be significantly associated with active ocular inflammation, (odds ratio: 0.01, 95% confidence interval: 0.00004\u20130.81; <jats:italic>p<\/jats:italic>\u2009=\u20090.04).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>SAF AGE level was not so far found to be a reliable biomarker for indicating uveitis\/scleritis activity in systemic immune-related disease patients with active ocular inflammation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial registration<\/jats:title>\n            <jats:p>Thai Clinical Trials Registry, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.thaiclinicaltrials.org\/\" ext-link-type=\"uri\">https:\/\/www.thaiclinicaltrials.org\/<\/jats:ext-link>. (Reg. No. TCTR20200114004, registered date 01\/01\/2020, beginning date of the trial 10\/01\/2019).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10792-024-02980-7","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T14:03:04Z","timestamp":1707400984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between advanced glycation end products and uveitis\/scleritis activity in patients with active immune-mediated ocular inflammatory diseases"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"tctr20200114004","registry":"10.18810\/tctr"}],"author":[{"given":"Nutchaya","family":"Sukon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pitipol","family":"Choopong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usanee","family":"Tungsattayathitthan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattaporn","family":"Tesavibul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilawan","family":"Sanpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutasinee","family":"Boonsopon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"issue":"2","key":"2980_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s001250051591","volume":"44","author":"R Singh","year":"2001","unstructured":"Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44(2):129\u2013146. https:\/\/doi.org\/10.1007\/s001250051591","journal-title":"Diabetologia"},{"key":"2980_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2019.108843","volume":"129","author":"I Gonzalez","year":"2020","unstructured":"Gonzalez I, Morales MA, Rojas A (2020) Polyphenols and AGEs\/RAGE axis. Trends and challenges. Food Res Int 129:108843. https:\/\/doi.org\/10.1016\/j.foodres.2019.108843","journal-title":"Food Res Int"},{"key":"2980_CR3","doi-asserted-by":"publisher","first-page":"7989180","DOI":"10.1155\/2017\/7989180","volume":"2017","author":"A Guerin-Dubourg","year":"2017","unstructured":"Guerin-Dubourg A, Cournot M, Planesse C, Debussche X, Meilhac O, Rondeau P et al (2017) Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. Biomed Res Int 2017:7989180. https:\/\/doi.org\/10.1155\/2017\/7989180","journal-title":"Biomed Res Int"},{"issue":"6","key":"2980_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/bjo.85.6.746","volume":"85","author":"AW Stitt","year":"2001","unstructured":"Stitt AW (2001) Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 85(6):746\u2013753. https:\/\/doi.org\/10.1136\/bjo.85.6.746","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"2980_CR5","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1016\/j.bbadis.2018.08.036","volume":"1864","author":"S Rowan","year":"2018","unstructured":"Rowan S, Bejarano E, Taylor A (2018) Mechanistic targeting of advanced glycation end-products in age-related diseases. Biochim Biophys Acta Mol Basis Dis 1864(12):3631\u20133643. https:\/\/doi.org\/10.1016\/j.bbadis.2018.08.036","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"2980_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.sjopt.2018.05.002","volume":"32","author":"AS Al-Kharashi","year":"2018","unstructured":"Al-Kharashi AS (2018) Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy. Saudi J Ophthalmol 32(4):318\u2013323. https:\/\/doi.org\/10.1016\/j.sjopt.2018.05.002","journal-title":"Saudi J Ophthalmol"},{"issue":"6","key":"2980_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1189\/jlb.3A0513-288RRR","volume":"96","author":"Z Dong","year":"2014","unstructured":"Dong Z, Iwata D, Kitaichi N, Takeuchi M, Sato M, Endo N et al (2014) Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation. J Leukoc Biol 96(6):1077\u20131085. https:\/\/doi.org\/10.1189\/jlb.3A0513-288RRR","journal-title":"J Leukoc Biol"},{"issue":"3","key":"2980_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF03345377","volume":"28","author":"ME Garay-Sevilla","year":"2005","unstructured":"Garay-Sevilla ME, Regalado JC, Malacara JM, Nava LE, Wrobel-Zasada K, Castro-Rivas A et al (2005) Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest 28(3):223\u2013230. https:\/\/doi.org\/10.1007\/BF03345377","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2980_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00125-004-1451-2","volume":"47","author":"R Meerwaldt","year":"2004","unstructured":"Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL et al (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47(7):1324\u20131330. https:\/\/doi.org\/10.1007\/s00125-004-1451-2","journal-title":"Diabetologia"},{"issue":"3","key":"2980_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/dc07-1755","volume":"31","author":"EG Gerrits","year":"2008","unstructured":"Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ et al (2008) Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31(3):517\u2013521. https:\/\/doi.org\/10.2337\/dc07-1755","journal-title":"Diabetes Care"},{"issue":"12","key":"2980_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/iub.1450","volume":"67","author":"JM Ashraf","year":"2015","unstructured":"Ashraf JM, Ahmad S, Choi I, Ahmad N, Farhan M, Tatyana G et al (2015) Recent advances in detection of AGEs: immunochemical, bioanalytical and biochemical approaches. IUBMB Life 67(12):897\u2013913. https:\/\/doi.org\/10.1002\/iub.1450","journal-title":"IUBMB Life"},{"key":"2980_CR12","doi-asserted-by":"publisher","first-page":"3818196","DOI":"10.1155\/2020\/3818196","volume":"2020","author":"A Perrone","year":"2020","unstructured":"Perrone A, Giovino A, Benny J, Martinelli F (2020) Advanced glycation end products (AGEs): biochemistry, signaling, analytical methods, and epigenetic effects. Oxid Med Cell Longev 2020:3818196. https:\/\/doi.org\/10.1155\/2020\/3818196","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"2980_CR13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1097\/01.asn.0000067413.32377.cf","volume":"14","author":"ME Suliman","year":"2003","unstructured":"Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E et al (2003) Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 14(6):1614\u20131622. https:\/\/doi.org\/10.1097\/01.asn.0000067413.32377.cf","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2980_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/bbrc.1998.8203","volume":"244","author":"T Miyata","year":"1998","unstructured":"Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H et al (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244(1):45\u201349. https:\/\/doi.org\/10.1006\/bbrc.1998.8203","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2980_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509\u201316. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2980_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","volume":"118","author":"HN Sen","year":"2011","unstructured":"Sen HN, Sangave AA, Goldstein DA, Suhler EB, Cunningham D, Vitale S et al (2011) A standardized grading system for scleritis. Ophthalmology 118(4):768\u2013771. https:\/\/doi.org\/10.1016\/j.ophtha.2010.08.027","journal-title":"Ophthalmology"},{"issue":"1","key":"2980_CR17","first-page":"56","volume":"23","author":"VM dos Santos","year":"2015","unstructured":"dos Santos VM, Fachinelli LR, Farage L, de Souza Lima G, Machado de Carvalho MR, Nogueira de Andrade IG (2015) An 81-year-old male with iliopsoas abscess by Streptococcus sanguis. Infez Med 23(1):56\u201360","journal-title":"Infez Med"},{"issue":"5","key":"2980_CR18","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1167\/iovs.08-2709","volume":"50","author":"T Watanabe","year":"2009","unstructured":"Watanabe T, Keino H, Sato Y, Kudo A, Kawakami H, Okada AA (2009) High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 50(5):2283\u20132290. https:\/\/doi.org\/10.1167\/iovs.08-2709","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt B","key":"2980_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.biocel.2016.06.016","volume":"81","author":"NL Reynaert","year":"2016","unstructured":"Reynaert NL, Gopal P, Rutten EPA, Wouters EFM, Schalkwijk CG (2016) Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol 81(Pt B):403\u2013418. https:\/\/doi.org\/10.1016\/j.biocel.2016.06.016","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"2980_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/nutrit\/nuv030","volume":"73","author":"NJ Kellow","year":"2015","unstructured":"Kellow NJ, Coughlan MT (2015) Effect of diet-derived advanced glycation end products on inflammation. Nutr Rev 73(11):737\u2013759. https:\/\/doi.org\/10.1093\/nutrit\/nuv030","journal-title":"Nutr Rev"},{"key":"2980_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ymeth.2021.12.008","volume":"203","author":"D Corica","year":"2022","unstructured":"Corica D, Pepe G, Curro M, Aversa T, Tropeano A, Ientile R et al (2022) Methods to investigate advanced glycation end-product and their application in clinical practice. Methods 203:90\u2013102. https:\/\/doi.org\/10.1016\/j.ymeth.2021.12.008","journal-title":"Methods"},{"issue":"6","key":"2980_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1562\/0031-8655(2003)077<0616:ioetpa>2.0.co;2","volume":"77","author":"J Sandby-Moller","year":"2003","unstructured":"Sandby-Moller J, Poulsen T, Wulf HC (2003) Influence of epidermal thickness, pigmentation and redness on skin autofluorescence. Photochem Photobiol 77(6):616\u2013620. https:\/\/doi.org\/10.1562\/0031-8655(2003)077%3c0616:ioetpa%3e2.0.co;2","journal-title":"Photochem Photobiol"},{"issue":"11","key":"2980_CR23","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/bjo.2005.072678","volume":"89","author":"M Kitamura","year":"2005","unstructured":"Kitamura M, Kitaichi N, Takeuchi M, Kitamei H, Namba K, Yamagishi SI et al (2005) Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 89(11):1407\u20131409. https:\/\/doi.org\/10.1136\/bjo.2005.072678","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"2980_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1136\/bjo.80.11.1002","volume":"80","author":"K Norose","year":"1996","unstructured":"Norose K, Yano A (1996) Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 80(11):1002\u20131008. https:\/\/doi.org\/10.1136\/bjo.80.11.1002","journal-title":"Br J Ophthalmol"},{"key":"2980_CR25","doi-asserted-by":"publisher","first-page":"27848","DOI":"10.1038\/srep27848","volume":"6","author":"EJ Lee","year":"2016","unstructured":"Lee EJ, Kim JY, Oh SH (2016) Advanced glycation end products (AGEs) promote melanogenesis through receptor for AGEs. Sci Rep 6:27848. https:\/\/doi.org\/10.1038\/srep27848","journal-title":"Sci Rep"},{"issue":"1","key":"2980_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/bjo.83.1.39","volume":"83","author":"N Yawata","year":"1999","unstructured":"Yawata N, Nakamura S, Kijima M, Ikai N, Kanai M, Sugita M et al (1999) High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 83(1):39\u201342. https:\/\/doi.org\/10.1136\/bjo.83.1.39","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"2980_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12603-010-0105-y","volume":"14","author":"RD Semba","year":"2010","unstructured":"Semba RD, Beck J, Sun K, Egan JM, Carlson OD, Varadhan R et al (2010) Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: the Baltimore Longitudinal Study of Aging. J Nutr Health Aging 14(7):507\u2013513. https:\/\/doi.org\/10.1007\/s12603-010-0105-y","journal-title":"J Nutr Health Aging"},{"issue":"6","key":"2980_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1507\/endocrj.51.537","volume":"51","author":"K Hirata","year":"2004","unstructured":"Hirata K, Kubo K (2004) Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 51(6):537\u2013544. https:\/\/doi.org\/10.1507\/endocrj.51.537","journal-title":"Endocr J"},{"key":"2980_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.exer.2018.08.017","volume":"178","author":"E Bejarano","year":"2019","unstructured":"Bejarano E, Taylor A (2019) Too sweet: problems of protein glycation in the eye. Exp Eye Res 178:255\u2013262. https:\/\/doi.org\/10.1016\/j.exer.2018.08.017","journal-title":"Exp Eye Res"},{"key":"2980_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.freeradbiomed.2013.11.025","volume":"67","author":"PB Pun","year":"2014","unstructured":"Pun PB, Logan A, Darley-Usmar V, Chacko B, Johnson MS, Huang GW et al (2014) A mitochondria-targeted mass spectrometry probe to detect glyoxals: implications for diabetes. Free Radic Biol Med 67:437\u2013450. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.11.025","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"2980_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1753944713513061","volume":"7","author":"A Rastogi","year":"2013","unstructured":"Rastogi A (2013) Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis 7(6):322\u2013342. https:\/\/doi.org\/10.1177\/1753944713513061","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"2","key":"2980_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/157339912799424528","volume":"8","author":"A Elosta","year":"2012","unstructured":"Elosta A, Ghous T, Ahmed N (2012) Natural products as anti-glycation agents: possible therapeutic potential for diabetic complications. Curr Diabetes Rev 8(2):92\u2013108. https:\/\/doi.org\/10.2174\/157339912799424528","journal-title":"Curr Diabetes Rev"},{"key":"2980_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/896536","volume":"2013","author":"SI Franke","year":"2013","unstructured":"Franke SI, Muller LL, Santos MC, Fishborn A, Hermes L, Molz P et al (2013) Vitamin C intake reduces the cytotoxicity associated with hyperglycemia in prediabetes and type 2 diabetes. Biomed Res Int 2013:896536. https:\/\/doi.org\/10.1155\/2013\/896536","journal-title":"Biomed Res Int"},{"key":"2980_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1196\/annals.1333.090","volume":"1043","author":"N Karachalias","year":"2005","unstructured":"Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ (2005) High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 1043:777\u2013783. https:\/\/doi.org\/10.1196\/annals.1333.090","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2980_CR35","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.freeradbiomed.2009.11.019","volume":"48","author":"S Pashikanti","year":"2010","unstructured":"Pashikanti S, de Alba DR, Boissonneault GA, Cervantes-Laurean D (2010) Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radic Biol Med 48(5):656\u2013663. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2009.11.019","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"2980_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbrc.2010.01.095","volume":"393","author":"R Nagai","year":"2010","unstructured":"Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y (2010) Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun 393(1):118\u2013122. https:\/\/doi.org\/10.1016\/j.bbrc.2010.01.095","journal-title":"Biochem Biophys Res Commun"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-02980-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-02980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:23:53Z","timestamp":1741879433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-02980-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2980"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-02980-7","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol for this study was approved by the Siriraj Institutional Review Board (SIRB) (Approval No. SI 670\/2019, Approval Date 30\/9\/2019). This study adhered to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"33"}}